Serum Cytokines Correlate with Pretreatment Body Mass Index-adjusted Body Weight Loss Grading and Cancer Progression in Patients with Stage III Esophageal Squamous Cell Carcinoma Undergoing Neoadjuvant Chemoradiotherapy Followed by Surgery

References

• Chela HK, Gangu K, Ertugrul H, Juboori AA, Daglilar E, Tahan V. The 8th wonder of the cancer world: esophageal cancer and inflammation. Diseases. 2022;10(3):44. doi: 10.3390/diseases10030044.
   PubMedGoogle Scholar
• Lin R, Zhang C, Zheng J, Tian D, Lei Z, Chen D, Xu Z, Su M. Chronic inflammation-associated genomic instability paves the way for human esophageal carcinogenesis. Oncotarget. 2016;7(17):24564–24571. doi: 10.18632/oncotarget.8356.
   PubMedGoogle Scholar
• Sharma T, Gupta A, Chauhan R, Bhat AA, Nisar S, Hashem S, Akhtar S, Ahmad A, Haris M, Singh M, et al. Cross-talk between the microbiome and chronic inflammation in esophageal cancer: potential driver of oncogenesis. Cancer Metastasis Rev. 2022;41(2):281–299. doi: 10.1007/s10555-022-10026-6.
   PubMed Web of Science ®Google Scholar
• Jiang Y, Xu D, Song H, Qiu B, Tian D, Li Z, Ji Y, Wang J. Inflammation and nutrition-based biomarkers in the prognosis of oesophageal cancer: a systematic review and meta-analysis. BMJ Open. 2021;11(9):e048324. doi: 10.1136/bmjopen-2020-048324.
   PubMed Web of Science ®Google Scholar
• Sugawara K, Yagi K, Uemura Y, Okumura Y, Nishida M, Aikou S, Yamashita H, Seto H. Associations of systemic inflammation and sarcopenia with survival of esophageal carcinoma patients. Ann Thorac Surg. 2020;110(2):374–382. doi: 10.1016/j.athoracsur.2020.03.013.
   PubMed Web of Science ®Google Scholar
• Akhtar S. Areca nut chewing and esophageal squamous-cell carcinoma risk in Asians: a meta-analysis of case-control studies. Cancer Causes Control. 2013;24(2):257–265. doi: 10.1007/s10552-012-0113-9.
   PubMed Web of Science ®Google Scholar
• Yang CS, Chen X, Tu S. Etiology and prevention of esophageal cancer. Gastrointest Tumors. 2016;3(1):3–16. doi: 10.1159/000443155.
   PubMed Web of Science ®Google Scholar
• Grotenhuis BA, Wijnhoven BPL, Hötte GJ, van der Stok EP, Tilanus HW, van Lanschot JJB. Prognostic value of body mass index on short-term and long-term outcome after resection of esophageal cancer. World J Surg. 2010;34(11):2621–2627. doi: 10.1007/s00268-010-0697-8.
   PubMed Web of Science ®Google Scholar
• Ishibashi Y, Tsujimoto H, Yaguchi Y, Kishi Y, Ueno H. Prognostic significance of systemic inflammatory markers in esophageal cancer: systematic review and meta-analysis. Ann Gastroenterol Surg. 2020;4(1):56–63. doi: 10.1002/ags3.12294.
   PubMed Web of Science ®Google Scholar
• Tuomisto AE, Mäkinen MJ, Väyrynen JP. Systemic inflammation in colorectal cancer: underlying factors, effects, and prognostic significance. World J Gastroenterol. 2019;25(31):4383–4404. doi: 10.3748/wjg.v25.i31.4383.
   PubMed Web of Science ®Google Scholar
• Sohda M, Sakai M, Yamaguchi A, Watanabe T, Nakazawa N, Ubukata Y, Kuriyam K, Sano A, Yokobori T, Ogawa H, et al. Pre-treatment CRP and albumin determines prognosis for unresectable advanced esophageal cancer. In Vivo. 2022;36(4):1930–1936. doi: 10.21873/invivo.12914.
   PubMed Web of Science ®Google Scholar
• Wang CY, Hsieh MJ, Chiu YC, Li SH, Huang HW, Fang FM, Huang YJ. Higher serum C-reactive protein concentration and hypoalbuminemia are poor prognostic indicators in patients with esophageal cancer undergoing radiotherapy. Radiother Oncol. 2009;92(2):270–275. doi: 10.1016/j.radonc.2009.01.002.
   PubMed Web of Science ®Google Scholar
• Wang Y, Hu X, Huang Y, Xu WY, Wu YM, Li PF, Che GW. Prognostic value of the C-reactive protein to albumin ratio in esophageal cancer: a systematic review and meta-analysis. Kaohsiung J Med Sci. 2020;36(1):54–61. doi: 10.1002/kjm2.12129.
   PubMed Web of Science ®Google Scholar
• Yu X, Wen Y, Lin Y, Zhang X, Chen Y, Wang W, Wang G, Zhang L. The value of preoperative Glasgow Prognostic Score and the C-reactive protein to albumin ratio as prognostic factors for long-term survival in pathological T1N0 esophageal squamous cell carcinoma. J Cancer. 2018;9(5):807–815. doi: 10.7150/jca.22755.
   PubMed Web of Science ®Google Scholar
• Bhat AA, Nisar S, Maacha S, Carneiro-Lobo TC, Akhtar S, Siveen KS, Wani NA, Rizwan A, Bagga P, Singh M, et al. Cytokine-chemokine network driven metastasis in esophageal cancer; promising avenue for targeted therapy. Mol Cancer. 2021;20(1):2. doi: 10.1186/s12943-020-01294-3.
   PubMed Web of Science ®Google Scholar
• Chen CL, Wang Y, Huang CY, Zhou ZQ, Zhao JJ, Zhang XF, Pan QZ, Wu JX, Weng DS, Tang Y, et al. IL-17 induces antitumor immunity by promoting beneficial neutrophil recruitment and activation in esophageal squamous cell carcinoma. Oncoimmunology. 2017;7(1):e1373234. doi: 10.1080/2162402X.2017.1373234.
   PubMed Web of Science ®Google Scholar
• Chen MF, Chen PT, Lu MS, Lin PY, Chen WC, Lee KD. IL-6 expression predicts treatment response and outcome in squamous cell carcinoma of the esophagus. Mol Cancer. 2013;12(1):26. doi: 10.1186/1476-4598-12-26.
   PubMedGoogle Scholar
• Goto M, Liu M. Chemokines and their receptors as biomarkers in esophageal cancer. Esophagus. 2020;17(2):113–121. doi: 10.1007/s10388-019-00706-8.
   PubMed Web of Science ®Google Scholar
• Maeda Y, Takeuchi H, Matsuda S, Okamura A, Fukuda K, Miyasho T, Nakamura R, Suda K, Wada N, Kawakubo H, et al. Clinical significance of preoperative serum concentrations of interleukin-6 as a prognostic marker in patients with esophageal cancer. Esophagus. 2020;17(3):279–288. doi: 10.1007/s10388-019-00708-6.
   PubMed Web of Science ®Google Scholar
• Pastrez PRA, Barbosa AM, Mariano VS, Causin RL, Castro AG, Torrado E, Longatto-Filho A. Interleukin-8 and interleukin-6 are biomarkers of poor prognosis in esophageal squamous cell carcinoma. Cancers. 2023;15(7):1997. doi: 10.3390/cancers1507.
   PubMed Web of Science ®Google Scholar
• Rebernick RJ, Bell HN, Bauer TM, McEwen D, Werkman DF, Chang AC, Lin J, Reddy RM, Kresty L, Lagisetty K. Role of IL4 and GMCSF in predicting survival in esophageal cancer. J Am Coll Surg. 2023;236(1):107–115. doi: 10.1097/XCS.0000000000000446.
   PubMed Web of Science ®Google Scholar
• Shinsyu A, Bamba S, Kurihara M, Matsumoto H, Sonoda A, Inatomi O, Andoh A, Takebayashi K, Kojima M, Iida H, et al. Inflammatory cytokines, appetite-regulating hormones, and energy metabolism in patients with gastrointestinal cancer. Oncol Lett. 2020;20(2):1469–1479. doi: 10.3892/ol.2020.11662.
   PubMed Web of Science ®Google Scholar
• Pan W, Sun Z, Xiang Y, Fang W. The correlation between high body mass index and survival in patients with esophageal cancer after curative esophagectomy: evidence from retrospective studies. Asia Pac J Clin Nutr. 2015;24(3):480–488. doi: 10.6133/apjcn.2015.24.3.05.
   PubMed Web of Science ®Google Scholar
• Smith M, Zhou M, Whitlock G, Yang G, Offer A, Hui G, Peto R, Huang Z, Chen Z. Esophageal cancer and body mass index: results from a prospective study of 220,000 men in China and a meta-analysis of published studies. Int J Cancer. 2008;122(7):1604–1610. doi: 10.1002/ijc.23198.
   PubMed Web of Science ®Google Scholar
• Martin L, Senesse P, Gioulbasanis I, Antoun S, Bozzetti F, Deans C, Strasser F, Thoresen L, Jagoe RT, Chasen M, et al. Diagnostic criteria for the classification of cancer-associated weight loss. J Clin Oncol. 2015;33(1):90–99. doi: 10.1200/JCO.2014.56.1894.
   PubMed Web of Science ®Google Scholar
• Pan YP, Kuo HC, Hsu TY, Lin JY, Chou WC, Lai CH, Chang PH, Yeh KY. Body mass index-adjusted body weight loss grading predicts overall survival in esophageal squamous cell carcinoma patients. Nutr Cancer. 2021;73(7):1130–1137. doi: 10.1080/01635581.2020.1792950.
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383. doi: 10.1016/0021-9681(87)90171-8.
   PubMedGoogle Scholar
• Pan YP, Chang PH, Fan CW, Tseng WK, Huang JS, Chen CH, Chou WC, Wang CH, Yeh KY. Relationship between pre-treatment nutritional status, serum glutamine, arginine levels and clinicopathological features in Taiwan colorectal cancer patients. Asia Pac J Clin Nutr. 2015;24(4):598–604. doi: 10.6133/apjcn.2015.24.4.23.
   PubMed Web of Science ®Google Scholar
• Engel LS, Chow WH, Vaughan TL, Gammon MD, Risch HA, Stanford JL, Schoenberg JB, Mayne ST, Dubrow R, Rotterdam M, et al. Population attributable risks of esophageal and gastric cancers. J Natl Cancer Inst. 2003;95(18):1404–1413. doi: 10.1093/jnci/djg047.
   PubMed Web of Science ®Google Scholar
• Hongo M, Nagasaki Y, Shoji T. Epidemiology of esophageal cancer: orient to Occident. Effects of chronology, geography and ethnicity. J Gastroenterol Hepatol. 2009;24(5):729–735. doi: 10.1111/j.1440-1746.2009.05824.x.
   PubMed Web of Science ®Google Scholar
• Bystricky B, Okines AF, Cunningham D. Optimal therapeutic strategies for resectable oesophageal or oesophagogastric junction cancer. Drugs. 2011;71(5):541–555. doi: 10.2165/11585460-000000000-00000.
   PubMed Web of Science ®Google Scholar
• Doki Y, Ajani JA, Kato K, Xu J, Wyrwicz L, Motoyama S, Ogata T, Kawakami H, Hsu CH, Adenis A, et al. Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma. N Engl J Med. 2022;386(5):449–462. doi: 10.1056/NEJMoa2111380.
   PubMed Web of Science ®Google Scholar
• Mariette C, Piessen G, Triboulet JP. Therapeutic strategies in oesophageal carcinoma: role of surgery and other modalities. Lancet Oncol. 2007;8(6):545–553. doi: 10.1016/S1470-2045(07)70172-9.
   PubMed Web of Science ®Google Scholar
• Okamura A, Watanabe M, Okui J, Matsuda S, Takemura R, Kawakubo H, Takeuchi H, Muto M, Kakeji Y, Kitagawa Y, et al. Risk prediction of esophageal squamous cell carcinoma recurrence in patients who underwent esophagectomy after receiving neoadjuvant treatment: a nationwide retrospective study in Japan. Esophagus. 2023;20(3):465–473. doi: 10.1007/s10388-023-01002-2.
   PubMed Web of Science ®Google Scholar
• Dewys WD, Begg C, Lavin PT, Band PR, Bennett JM, Bertino JR, Cohen MH, Douglass HOJr, Engstrom PF, Ezdinli EZ, et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med. 1980;69(4):491–497. doi: 10.1016/s0149-2918(05)80001-3.
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Arends J. The causes and consequences of cancer-associated malnutrition. Eur J Oncol Nurs. 2005;9 Suppl 2:s51–s63. doi: 10.1016/j.ejon.2005.09.007.
   PubMedGoogle Scholar
• Lippitz BE. Cytokine patterns in patients with cancer: a systematic review. Lancet Oncol. 2013;14(6):e218–e228. doi: 10.1016/S1470-2045(12)70582-X.
   PubMed Web of Science ®Google Scholar
• Ruan GT, Ge YZ, Xie HL, Hu CL, Zhang Q, Zhang X, Tang M, Song MM, Zhang XW, Liu T, et al. Association between systemic inflammation and malnutrition with survival in patients with cancer sarcopenia-a prospective multicenter study. Front Nutr. 2021;8:811288. doi: 10.3389/fnut.2021.811288.
   PubMed Web of Science ®Google Scholar
• Chen MF, Hsieh CC, Chen PT, Lu MS. Role of nutritional status in the treatment outcome for esophageal squamous cell carcinoma. Nutrients. 2021;13(9):2997. doi: 10.3390/nu13092997.
   PubMed Web of Science ®Google Scholar
• Krzystek-Korpacka M, Matusiewicz M, Diakowska D, Grabowski K, Blachut K, Kustrzeba-Wojcicka I, Banas T. Impact of weight loss on circulating IL-1, IL-6, IL-8, TNF-alpha, VEGF-A, VEGF-C and midkine in gastroesophageal cancer patients. Clin Biochem. 2007;40(18):1353–1360. doi: 10.1016/j.clinbiochem.2007.07.013.
   PubMed Web of Science ®Google Scholar
• Lu ZH, Yang L, Yu JW, Lu M, Li J, Zhou J, Wang XC, Gong JF, Gao J, Zhang XT, et al. Weight loss correlates with macrophage inhibitory cytokine-1 expression and might influence outcome in patients with advanced esophageal squamous cell carcinoma. Asian Pac J Cancer Prev. 2014;15(15):6047–6052. doi: 10.7314/apjcp.2014.15.15.6047.
   PubMedGoogle Scholar
• de Matos-Neto EM, Lima JDCC, de Pereira WO, Figuerêdo RG, Riccardi DMDR, Radloff K, das Neves RX, Camargo RG, Maximiano LF, Tokeshi F, et al. Systemic inflammation in cachexia – is tumor cytokine expression profile the culprit? Front Immunol. 2015;6:629. doi: 10.3389/fimmu.2015.00629.
   PubMed Web of Science ®Google Scholar
• Malla J, Zahra A, Venugopal S, Selvamani TY, Shoukrie SI, Selvaraj R, Dhanoa RK, Hamouda RK, Mostafa J. What role do inflammatory cytokines play in cancer cachexia? Cureus. 2022;14(7):e26798. doi: 10.7759/cureus.26798.
   PubMed Web of Science ®Google Scholar
• Mangano GD, Fouani M, D’Amico D, Di Felice V, Barone R. Cancer-related cachexia: the vicious circle between inflammatory cytokines, skeletal muscle, lipid metabolism and the possible role of physical training. Int J Mol Sci. 2022;23(6):3004. doi: 10.3390/ijms23063004.
   PubMed Web of Science ®Google Scholar
• Webster JM, Kempen L, Hardy RS, Langen RCJ. Inflammation and skeletal muscle wasting during cachexia. Front Physiol. 2020;11:597675. doi: 10.3389/fphys.2020.597675.
   PubMed Web of Science ®Google Scholar
• Ko H, Il Kim Y, Ahn HJ. Activin Suppresses the inflammatory response of TNF-alpha -stimulated human umbilical vein endothelial cells. Pharmazie. 2022;77(5):152–156. doi: 10.1691/ph.2022.2330.
   PubMed Web of Science ®Google Scholar
• Walton KL, Chen JL, Arnold Q, Kelly E, La M, Lu L, Lovrecz G, Hagg A, Colgan TD, Qian H, et al. Activin A-induced cachectic wasting is attenuated by systemic delivery of its cognate propeptide in male mice. Endocrinology. 2019;160(10):2417–2426. doi: 10.1210/en.2019-00257.
   PubMed Web of Science ®Google Scholar
• Torres KC, Dutra WO, Gollob KJ. Endogenous IL-4 and IFN-gamma are essential for expression of Th2, but not Th1 cytokine message during the early differentiation of human CD4+ T helper cells. Hum Immunol. 2004;65(11):1328–1335. doi: 10.1016/j.humimm.2004.06.007.
   PubMed Web of Science ®Google Scholar
• Hallett MA, Venmar KT, Fingleton B. Cytokine stimulation of epithelial cancer cells: the similar and divergent functions of IL-4 and IL-13. Cancer Res. 2012;72(24):6338–6343. doi: 10.1158/0008-5472.CAN-12-3544.
   PubMed Web of Science ®Google Scholar
• Xin Z, Wenyu F, Shenhua X. Clinicopathologic significance of cytokine levels in esophageal squamous cell carcinoma. Hepatogastroenterology. 2010;57(104):1416–1422.
   PubMedGoogle Scholar
• Chen S, Cao R, Liu C, Tang W, Kang M. Investigation of IL-4, IL-10, and HVEM polymorphisms with esophageal squamous cell carcinoma: a case-control study involving 1929 participants. Biosci Rep. 2020;40(8):BSR20193895. doi: 10.1042/BSR20193895.
   PubMedGoogle Scholar
• Wang J, Chen T, Tang W, Kang M, Chen S. Associations of interleukin-4 and interleukin-4 receptor loci with esophageal squamous cell carcinoma susceptibility. Int Immunopharmacol. 2021;97:107659. doi: 10.1016/j.intimp.2021.107659.
   PubMed Web of Science ®Google Scholar
• Heimberger AB, Tripathi S, Platanias LC. Targeting cytokines and their pathways for the treatment of cancer. Cancers. 2023;15(21):5224. doi: 10.3390/cancers15215224.
   PubMed Web of Science ®Google Scholar
• Lan T, Chen L, Wei X. Inflammatory cytokines in cancer: comprehensive understanding and clinical progress in gene therapy. Cells. 2021;10(1):100. doi:10.3390/cells10010100.
   PubMed Web of Science ®Google Scholar
• Chang KJ, Reid T, Senzer N, Swisher S, Pinto H, Hanna N, Chak A, Soetikno R. Phase I evaluation of TNFerade biologic plus chemoradiotherapy before esophagectomy for locally advanced resectable esophageal cancer. Gastrointest Endosc. 2012;75(6):1139.e2–1146.e2. doi:10.106/j.gie.2012.01.042.
   Web of Science ®Google Scholar